Company Overview of Mercator MedSystems, Inc.
Mercator MedSystems, Inc., a medical technology company, develops catheter-guided microfluid injection systems for site-specific delivery of therapeutic agents directly across various blood vessels. The company offers Cricket and Bullfrog micro-infusion catheters, which are designed to inject therapeutic agents directly and non-systemically through blood vessel walls into deep tissues. It offers products for the treatment of blood vessel restenosis caused by inflammation after vascular injury; micro-infusion devices to infuse drugs, genes, and cells without material loss in viability or potency; inflammation and restenosis treatment for peripheral artery disease; and micro-infusion catheter ...
2200 Powell Street
Emeryville, CA 94608
Founded in 1999
Key Executives for Mercator MedSystems, Inc.
Chief Executive Officer and Director
Co-Founder, President and Chief Science & Technology Officer
Compensation as of Fiscal Year 2016.
Mercator MedSystems, Inc. Key Developments
Mercator MedSystems, Inc. Announces First Patient Enrolled in Below the Knee Clinical Trial
Jan 21 16
Mercator MedSystems, Inc. announced their first patient enrollment from Bad Krozingen, Germany, in the company's LIMBO-PTA clinical trial. This trial combines localized drug delivery using the company's proprietary Bullfrog Micro-Infusion Device of an off-the-shelf anti-inflammatory steroid (dexamethasone) with angioplasty. The study measures the benefit of adding drug delivery to the catheter-based re-opening of arteries below the knee in patients suffering from critical limb ischemia (CLI). In vessels below the knee, while balloon angioplasty is able to open the clogged artery, a scarring process usually leads to re-obstruction of the vessel within 6 months of the procedure. The purpose of locally delivering an inexpensive generic anti-inflammatory drug to the vessel is to extinguish the biological signals that cause the buildup of scar tissue and lead to restenosis. Two CLI trials are planned by Mercator, both of which are randomized, controlled trials: the German study (LIMBO-PTA), which pairs the therapy with angioplasty, and a United States study (LIMBO-ATX) which combines the therapy with atherectomy and has been submitted to the FDA. In angioplasty procedures, a high-pressure balloon is used to compress plaque and force the artery open, while atherectomy utilizes catheters with cutting blades or rough spinning surfaces to physically remove plaque from the artery. Both of these procedures are well known to cause blood vessel inflammation that leads to the re-occlusive scarring process.
Mercator MedSystems, Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 02:40 PM
Oct 31 15
Mercator MedSystems, Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 02:40 PM. Venue: Westin Grand Central, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries